Fingolimod (FTY720) HCl

Catalog No.S5002

For research use only.

Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.

Fingolimod (FTY720) HCl Chemical Structure

CAS No. 162359-56-0

Selleck's Fingolimod (FTY720) HCl has been cited by 91 publications

Purity & Quality Control

Choose Selective S1P Receptor Inhibitors

Other S1P Receptor Products

Biological Activity

Description Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.
Targets
S1P receptor [1]
(K562, NK cells )
0.033 nM
In vitro

The inhibitory effect of S1P is revered by various concentrations of FTY720, with IC50 effect of 173 nM. In addition, FTY720 (10 nM) alone exerts no effect on the expression of co-stimulatory molecules. FTY720 reverses the increased expression of HLA-I induced by S1P for both the percentages of cells and the MFI, upon comparing the effect of S1P to the effect of combining S1P with FTY720. [1] Medium and high-dose FTY720-P also enhances the levels of TGF-β1. TGF-β1 and Foxp3 mRNA expression are upregulated in the high-dose FTY720-P group. The proliferation of effector T cells is suppressed significantly in the medium and high-dose FTY720-P group at a Treg/Teff cell ratio of 1:1. At a ratio of 1:1, the proliferation of effector T cells is also suppressed in the high-dose FTY720 group. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human U2OS cells M1;zW2Z2dmO2aX;uJIF{e2G7 NH7FRVFC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHMyWDFicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJIh2dWGwIGWyU3Mh[2WubIOgZ48u\XiycnXzd4lv\yCnR1\QJIF{e2W|c3XkJIF{KHKnY3XweI9zKGmwdHXycoFtcXqjdHnvckBqdnSxIHP5eI9xdGG|bTD1d4lv\yCKb3XjbJN1KGS7ZTDzeIFqdmmwZzygSWM2OD1yLkCwNkDPxE1w Mnr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzMESxOFQoRjJ{MUC0NVQ1RC:jPh?=
human PC3 cells NX:wc24{S3m2b4TvfIlkyqCjc4PhfS=> NWGxbGo{PzJiaB?= MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7II\peIFtKGS7ZTDlfINtfXOrb36v[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTlwODFOwG0v NXfLRlh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO|M3OzJpPkK0Nlc{PjN{PD;hQi=>
human NALM6 cells MUjDfZRwfG:6aXRCpIF{e2G7 MnzQO|IhcA>? Ml3jR5l1d3SxeHnjbZR6KGGpYXnud5QhWGhvbnXnZZRqfmViaIXtZY4hVkGOTU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVkvPiEQvF2u NYCzOmJ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO|M3OzJpPkK0Nlc{PjN{PD;hQi=>
human CCRF-CEM cells MWfDfZRwfG:6aXRCpIF{e2G7 NGnqNJY4OiCq MkHqR5l1d3SxeHnjbZR6KGGpYXnud5QhWGhvbnXnZZRqfmViaIXtZY4hS0OURj3DSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7II\peIFtKGS7ZTDlfINtfXOrb36v[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTZwODFOwG0v NX2zZpBuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO|M3OzJpPkK0Nlc{PjN{PD;hQi=>
human SUP-B15 cells NE\sVoFEgXSxdH;4bYPDqGG|c3H5 M3;oOlczKGh? MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBRcC2yb4PpeIl3\SCqdX3hckBUXVBvQkG1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSC4aYThcEBlgWViZYjjcJV{cW:wL3\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyxiSVO1NF03NjhizszNMi=> NWXjbZVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO|M3OzJpPkK0Nlc{PjN{PD;hQi=>
human DU145 cells NUH6[oF4S3m2b4TvfIlkyqCjc4PhfS=> M2[5UVczKGh? MkT3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJZqfGGuIHT5[UBmgGOudYPpc44w\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPU[uOUDPxE1w NFXE[no9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N|Y{Oid-MkSyO|M3OzJ:L3G+
human BV173 cells NFTpd4ZEgXSxdH;4bYPDqGG|c3H5 MV63NkBp MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBRcC2yb4PpeIl3\SCqdX3hckBDXjF5MzDj[YxteyCjZoTldkA4OiCqcoOgZpkhfmm2YXyg[JlmKGW6Y3z1d4lwdi:obH;3JIN6fG:vZYTybYMh[W6jbInzbZMtKEmFNUC9Ok4{KM7:TT6= M2jLRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
human BLIN-1 cells NImyZVNEgXSxdH;4bYPDqGG|c3H5 NYXFTYtiPzJiaB?= NE\sV4lEgXSxdH;4bYNqfHliYXfhbY5{fCCSaD3u[YdifGm4ZTDoeY1idiCETFnOMVEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7II\peIFtKGS7ZTDlfINtfXOrb36v[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTVwNTFOwG0v NUX4fJF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO|M3OzJpPkK0Nlc{PjN{PD;hQi=>
mouse bone marrow cells NV3PNFlOS3m2b4TvfIlkyqCjc4PhfS=> MWW3NkBp MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBDS1JvQVLMJIZ2e2mxbjDwdo91\WmwIEG5NEBmgHC{ZYPzbY5oKG2xdYPlJIJwdmVibXHydo94KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTD2bZRidCCmeXWg[ZhkdHW|aX;uM4Ztd3diY4n0c41mfHKrYzDhcoFtgXOrczygTWM2OD1|LkOg{txONg>? M4nJR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
Sf9 insect cells Ml\lSpVv[3Srb36gZZN{[Xl? NFPZRm4yKGh? Mk\DTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCVMWDMJEg3OiC2bzC1OlgqKGW6cILld5Nm\CCrbjDT[lkhcW6|ZXP0JINmdGy|IIXzbY5oKFNzUDDhd{B{fWK|dILheIUh[W[2ZYKgNUBpeg>? NXTVSHBGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NFk5OTRpPkK0PFA6QDF2PD;hQi=>
mouse MN9D cells MYHGeY5kfGmxbjDhd5NigQ>? MoP6OUDPxE1? NVjBR4dLUW6mdXP0bY9vKG:oIGDQNmEh[2G2YXz5eIlkKHO3YoXubZQh[WO2aY\peJkhcW5ibX;1d4UhVU57RDDj[YxteyCjc4Pld5Nm\CCjczDwbI9{eGijdHWgcIV3\WxiYYSgOUB2VQ>? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3MEG2OUc,OjVyNUCxOlU9N2F-
rat PC12 cells NHP5SXJHfW6ldHnvckBie3OjeR?= MU[1JO69VQ>? NIWxTW4{OCC2bzCxNlAhdWmwcx?= M4PNZWlv\HWldHnvckBw\iCSUELBJINifGGueYTpZ{B{fWK3bnn0JIFkfGm4aYT5JIlvKHKjdDDQR|EzKGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbIF1\SCuZY\lcEBifCB3IIXNJI1m[XO3cnXkJFMxKHSxIEGyNEBucW6|Lh?= M{GyNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWwNVY2Lz5{NUC1NFE3PTxxYU6=
mouse MN9D cells NFzYXnRHfW6ldHnvckBie3OjeR?= NYPZUXQ1OC5zNjFOwG0> NWH4OmFuOjRiaB?= M2Xyfm5mfXKxcILveIVkfGm4ZTDhZ5Rqfmm2eTDpckBud3W|ZTDNUllFKGOnbHzzJIF{e2W|c3XkJIF{KHO2aX31cIF1cW:wIH;mJGJFVkZiZYjwdoV{e2mxbjDheEAxNjF4IIXNJIFnfGW{IEK0JIhzew>? NHvOOWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1NFE3PSd-MkWwOVAyPjV:L3G+
mouse MN9D cells NHK0e3BHfW6ldHnvckBie3OjeR?= MlzpNE4yPiEQvF2= MkHmO|IhcA>? NX;y[JdKVmW3cn;wdo91\WO2aY\lJIFkfGm4aYT5JIlvKG2xdYPlJG1PQURiY3XscJMh[XO|ZYPz[YQh[XNiYnzvZ4tqdmdib3[gWG5HNWGucHjhJIF{e2:laXH0[YQhfG:6aXPpeJkh[XRiMD6xOkB2VSCjZoTldkA4OiCqcoOgZpkhXHK7cHHuJIJtfWVic4ThbY5qdmdw M3vxTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWwNVY2Lz5{NUC1NFE3PTxxYU6=
CHO Mme2SpVv[3Srb36gZZN{[Xl? NF3TfYdFcXOybHHj[Y1mdnRib3[gX|M{WF2|cHjpcodwe2mwZTCxJJBpd3OyaHH0[UBnem:vIHj1cYFvKFNzUEGgdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyxiSVO1NF0xNjh2zszNMi=> NECzZYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[xOVUyOyd-MUW2NVU2OTN:L3G+
CHO MVfGeY5kfGmxbjDhd5NigQ>? M1e3bGRqe3CuYXPlcYVvfCCxZjDbN|NRZXOyaHnu[49{cW6nIEGgdIhwe3CqYYTlJIZzd21iaIXtZY4hWzGSNTDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{NCCLQ{WwQVIvOc7:TT6= M3vFTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkG1OVE{Lz5zNU[xOVUyOzxxYU6=
Jurkat MVLGeY5kfGmxbjDhd5NigQ>? MYKxPEBpenN? MmfiVoV3\XK|YXygc4YhcW6qaXLpeIlwdiCxZjDtbZRw[2ixbnTybYFtKG[3bnP0bY9vKGmwIHj1cYFvKEq3cnvheEBk\WyuczDh[pRmeiBzODDodpMhcW5icILld4Vv[2Vib3[gXk1XSURvZn3r NEPYdXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{SwNFU2PSd-MUe0NFA2PTV:L3G+
T-cells MWfGeY5kfGmxbjDhd5NigQ>? NFTQSHk6PiCqcoO= NYnESW9UUW2vdX7vd5VxeHKnc4PpeoUh[WO2aY\peJkhcW5iQlHMRk9kN0N3N1LMM|YhdW:3c3WgWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHscI9idnSrZ3XuMYlv\HWlZXSgZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEm2JIhzeyCkeTDt[YF{fXKrbnegX|NJZXSqeX3p[Ilv\SC3cIThb4Uh[nlibXn4[YQhdHmvcHjvZ5l1\SC{ZXHjeIlwdiCjc4PhfUwhUUN3ME2wMlAxPjIQvF2u MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
SK-BR-3 NXywTYRQSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NUXhcYFVPzhiaILz MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLVLSMVMh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|ghcHK|IHL5JHdUXC1zIHHzd4F6NCCLQ{WwQVXPxE1w M{nTWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
MDA-MB-231 MYHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M1jZU|c5KGi{cx?= MkXCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd6IHjyd{BjgSCZU2StNUBie3OjeTygTWM2OD13zszNMi=> Mo\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NU[1NlQoRjJzNEW2OVI1RC:jPh?=
HCT116 NUmyZm86SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NW\KOnY3PzhiaILz MVjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3PEBpenNiYomgW3NVNTFiYYPzZZktKEmFNUC9Oe69VS5? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
SW620 NXLt[mNuSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MknjO|ghcHK| Mo\kRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVV{[yNEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3PEBpenNiYomgW3NVNTFiYYPzZZktKEmFNUC9Oe69VS5? NX3F[VhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVY2OjRpPkKxOFU3PTJ2PD;hQi=>
MCF7 M3;VfGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NWS4SnNUPzhiaILz NX7id49FSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFc5KGi{czDifUBYW1RvMTDhd5NigSxiSVO1NF02|ryPLh?= NWD0NJFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVY2OjRpPkKxOFU3PTJ2PD;hQi=>
LNCAP-AI MU\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NHn4WpQ4QCCqcoO= NED0cW1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBpfW2jbjDMUmNCWC2DSTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5ODDodpMh[nliV2PUMVEh[XO|YYmsJGlEPTB;Nd88UU4> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
MGC803 M4faVGFvfGm2dX3vdkBie3OjeR?= NIe4WYsyOCCvZz;r[y=> NHX1[3QzOCCmYYnz M2exUGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3HR|gxOyClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueYRmKG2xdYPlJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JiZ4Lve5RpKGG2IEGwJI1oN2upIH\vdkAzOCCmYYnz NF3nNYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1OlUzPCd-MkG0OVY2OjR:L3G+
U2OS Mo\USpVv[3Srb36gZZN{[Xl? NUSxb4hTOThiaILz MnrlRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDTNXAyKHKnY3XweI9zKGW6cILld5Nm\CCrbjDFSGcyNWKuYTDVNm9UKGOnbHzzJIlv[3WkYYTl[EBnd3JiMUigbJJ{KHC{aX;yJJRwKEenblLsZZpmeiC|dXLzeJJifGViYXTkbZRqd25iYomgZoV1[S2jcoLld5RqdiC{ZXPyeYl1dWWwdDDhd5NigSxiRVO1NF0xNjByN{NOwG0v NEW4PWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[4O|Q5Pyd-Mk[2PFc1QDd:L3G+
FL5.12A M3yzUmN6fG:2b4jpZ4l1gSCjc4PhfS=> NUjiXplQPDhiaILz NX70cFF2S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhTkx3LkGyRUBk\WyuczDh[pRmeiB2ODDodpMh[nliRFHQTUB{fGGrbnnu[{1j[XOnZDDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:Oi52zszNMi=> M37PN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEe1OVM1Lz5{N{S3OVU{PDxxYU6=
SH-SY5Y NWDlTIxXS3m2b4TvfIlkcXS7IHHzd4F6 M{fJRlI1KGi{cx?= MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KG2nYYP1doVlKGGodHXyJFI1KGi{czDifUBkenm|dHHsMZZqd2yndDDzeIFqdmmwZzDiZZNm\CCjc4PhfUwhTUNzME2wMlU1|ryPLh?= M1Pue|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGzNVE2Lz5{N{mxN|EyPTxxYU6=
SK-N-SH M4T0XWN6fG:2b4jpZ4l1gSCjc4PhfS=> M1TLeFI1KGi{cx?= NIHib4VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2QLWPIJINmdGy|IH3lZZN2emWmIHHmeIVzKDJ2IHjyd{BjgSClconzeIFtNX[rb3zleEB{fGGrbnnu[{Bj[XOnZDDhd5NigSxiRVOxNF0xNjV3zszNMi=> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzM{GxOUc,Ojd7MUOxNVU9N2F-
U118MG NHnLWmlEgXSxdH;4bYNqfHliYYPzZZk> MkG1NlQhcHK| NXrZVY1vS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTFzOF3HJINmdGy|IH3lZZN2emWmIHHmeIVzKDJ2IHjyd{BjgSClconzeIFtNX[rb3zleEB{fGGrbnnu[{Bj[XOnZDDhd5NigSxiRVOxNF0xNjZzzszNMi=> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzM{GxOUc,Ojd7MUOxNVU9N2F-
SH-SY5Y NY\DOWlPTnWwY4Tpc44h[XO|YYm= MXPB[49vcXO2IHHjeIl3cXS7IHH0JJNxcGmwZ3;zbY5mNTFvcHjvd5Bp[XSnIILlZ4VxfG:{IHnuJIh2dWGwIGPIMXN[PVliY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZ2FOWCCuZY\lcEBifCCHQ{GwJIJ6KGSrcnXjeEBqdW23bn;hd5NigQ>? MmS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
U118MG MVPGeY5kfGmxbjDhd5NigQ>? NHnxeo9C\2:waYP0JIFkfGm4aYT5JIF1KHOyaHnu[49{cW6nLUGtdIhwe3CqYYTlJJJm[2WydH;yJIlvKGi3bXHuJHUyOTiPRzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBkSU2SIHzleoVtKGG2IFXDNVAh[nliZHny[YN1KGmvbYXuc4F{e2G7 MlzWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
SK-N-SH MXjGeY5kfGmxbjDhd5NigQ>? NE\KXY5C\2:waYP0JIFkfGm4aYT5JIF1KHOyaHnu[49{cW6nLUGtdIhwe3CqYYTlJJJm[2WydH;yJIh2dWGwIGPLMW4uW0hiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZ2FOWCCuZY\lcEBifCCHQ{GwJIJ6KGSrcnXjeEBqdW23bn;hd5NigQ>? NFXhR4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxN|EyPSd-Mke5NVMyOTV:L3G+
HEK293 NV\wWoZPTnWwY4Tpc44h[XO|YYm= MmDVNVghcHK| NVP3VVJkSWexbnnzeEBi[3Srdnn0fUBifCC|cHjpcodwe2mwZT2xMZBpd3OyaHH0[UBz\WOncITvdkApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iY1HNVEBt\X[nbDDheEBGSzFyIHHmeIVzKDF6IHjyd{BjgSCFUlWtdoV{eG:wc3n2[UBz\W6rbHzhJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? NGr3bpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxN|EyPSd-Mke5NVMyOTV:L3G+
SJ-GBM2 M1u4b5FJXFNiYYPzZZk> Mn7qdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= NF\3NoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
A673 MlLzdWhVWyCjc4PhfS=> MlvDdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? Mnq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC M2q4UZFJXFNiYYPzZZk> Mn3GdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= MoHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 M2ize5FJXFNiYYPzZZk> MUfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? NXX1U4dRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 NGXF[oZyUFSVIHHzd4F6 MWjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= NH\ydog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 M1vmNpFJXFNiYYPzZZk> M1uxTpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= MmP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH MV;xTHRUKGG|c3H5 M1LIfZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 M1nTXZFJXFNiYYPzZZk> M{DDW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= Mk\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 M{X5T5FJXFNiYYPzZZk> NX\jOog4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz M{TZXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 MYLxTHRUKGG|c3H5 Mnv1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy| Ml\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 MV3xTHRUKGG|c3H5 NUW0SFhMeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO= MlXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 NVnqS|NIeUiWUzDhd5NigQ>? NVq5[VJseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> NH;6Rms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD MVrxTHRUKGG|c3H5 M1zzVJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? NFf4W4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) M1jnZZFJXFNiYYPzZZk> NEj1[5lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO= Mo\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh30 NETDV4xyUFSVIHHzd4F6 MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh|MDDj[Yxtew>? NWrUPJV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 MYnxTHRUKGG|c3H5 NX;2WHBOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= MnHmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
FL5.12 M4TlWmN6fG:2b4jpZ4l1gSCjc4PhfS=> MoroOFghcHK| M133XWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGZNPS5zMjDj[YxteyCjZoTldkA1QCCqcoOgZpkhTEGSSTDvdkBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyxiSVO1NF0zNjIQvF2u NIjWbVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK5Nlg6QCd-M{CyPVI5QTh:L3G+
FL5.12 MXzDfZRwfG:6aXPpeJkh[XO|YYm= MoO5NVAhfU1? MVmzJIhzew>? MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDGUFUvOTJiY3XscJMh[XO|ZYPz[YQh[XNidnHjeY9t\SCob4LtZZRqd25iYYSgNVAhfU1iYX\0[ZIhOyCqcoOgZpkh\my3b4Lld4NmdmOnIH3pZ5Jwe2OxcHnjJIFv[Wy7c3nz NXrHNpJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyPVI5QThpPkOwNlkzQDl6PD;hQi=>
FL5.12 MljNR5l1d3SxeHnjbZR6KGG|c3H5 NH;B[JgzNjVidV2= NWjXVVZGOyCqcoO= MoLVR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgSmw2NjF{IHPlcIx{KGG|c3Xzd4VlKGG|II\hZ5VwdGViZn;ycYF1cW:wIHH0JFIvPSC3TTDh[pRmeiB|IHjyd{BjgSCobIXvdoV{[2WwY3WgcYlkem:|Y3;wbYMh[W6jbInzbZM> NGLXNFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK5Nlg6QCd-M{CyPVI5QTh:L3G+
HepG2 NH7ufItyUFSVIHHzd4F6 NEPjW2pJ\XCJMjDj[YxteyC4aXHibYxqfHlicVjUV{Bnd3JiWnnrZUB3cXK3czDpcohq[mm2b4Lz M3;YPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzN|MkK5OVQ2Lz5|M{KyPVU1PTxxYU6=
CHO M4XOU2Z2dmO2aX;uJIF{e2G7 MYHB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGOxVFMhemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPIU{Bk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiClYXzjbZVuKG[udYigZpkh[WWzdX;ybY4u\GW{aY\l[EBtfW2rbnXzZ4Vv[2ViYYPzZZktKEWFNUC9Nk42OTF6Od88UU4> Mln4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|E1QDV2Lze+R4hGVUKOPD;hQi=>
CHO M{DYbGZ2dmO2aX;uJIF{e2G7 M4LuNWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gV|FRPSC{ZXPldJRweiCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHPhcINqfW1iZnz1fEBjgSCjZYH1c5Jqdi2mZYLpeoVlKGy3bXnu[ZNk\W6lZTDhd5NigSxiRVO1NF0{NjF4MkK4{txONg>? MlPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|E1QDV2Lze+R4hGVUKOPD;hQi=>
Assay
Methods Test Index PMID
Western blot p-AKT / AKT / p-mTOR / mTOR / p-GSK3β / GSK3β / p-IKKα/β / IKKα / NF-κB / Survivin ; p-STAT3 / STAT3 / Bcl-xl / Bcl-2 / Bax ; Cyclin D1 / CDK4 / cyclin E / CDK2 / p27 / p16 28717222 25344679
Immunofluorescence NF-κB ; N-cadherin / Vimentin 28717222 25344679
Growth inhibition assay Cell viability 28717222
In vivo FTY720 is effective in Ph+ but not Ph- ALL xenografts using an early disease model. FTY720 produces a significant reduction in disease burden in the Ph+ ALL xenografts using an early disease model. Ph+ human ALL xenografts responds to FTY720 with an 80 % reduction in overall disease if treatment has been initiated early on. In contrast, treatment of mice with FTY720 does not result in reduced leukemia compared to controls using four separate human Ph- ALL xenografts. [3]

Protocol (from reference)

Cell Research:[1]
  • Cell lines: Immature DCs
  • Concentrations: 10 nM
  • Incubation Time: 4 hours
  • Method: Immature DCs are left intact or are incubated with 2 μM S1P, 10 nM FTY720, 10 nM SEW2871 or the combinations of S1P with these drugs for 4 hours. As a control 1 μg/mL LPS is used. The cells are washed and incubated in a 96-well plate (v-bottom, 2 × 105 cells per well), washed again and resuspended in PBS buffer containing 0.1% sodium azide. They are labeled with 1 μg/mL FITC-conjugated mouse anti-human CD80, 1 μg/mL FITC-conjugated mouse anti-human CD83, 1 μg/mL FITC-conjugated mouse anti-human CD86, 1 μg/mL FITC-conjugated mouse anti-human HLA-class I, 1 μg/mL FITC-conjugated mouse anti-human HLA-DR, 1 μg/mL FITC-conjugated mouse anti-human HLA-E, or 1 μg/mL FITC-conjugated mouse IgG as a control. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control FITC-conjugated mouse IgG. To stain NK cells with antibodies for various NK cell activating receptors, they are either left untreated or incubated with 2 μM S1P for 4 hours, washed and stained with 1 μg/mL PE-conjugated mouse anti-human NKp30 (CD337), 1 μg/mL PE-conjugated mouse anti-human NKp44 (CD336), 1 μg/mL PE-conjugated mouse anti-human NKG2D (CD314), or as a control 1 μg/mL PE-conjugated mouse IgG1, for 45 min at 4 °C. NK cells are also stained with 1 μg/mL FITC-conjugated anti-killer inhibitory receptor (KIR)/CD158 antibody which recognizes KIR2DL2, KIR2DL3, KIR2DS2 and KIR2DS4, and as a control with FITC-conjugated mouse IgG. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control PE-conjugated or FITC-conjugated mouse IgG.
  • (Only for Reference)
Animal Research:[3]
  • Animal Models: NOD/SCIDγc−/− mice bearing ALL cells.
  • Dosages: 5 mg/kg/day, 10 mg/kg/day
  • Administration: Administered via i.p.
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 69 mg/mL
(200.63 mM)
Water 69 mg/mL
(200.63 mM)
Ethanol ''69 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 343.9
Formula

C19H33NO2.HCl

CAS No. 162359-56-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05141669 Completed Drug: Fingolimod Multiple Sclerosis Novartis Pharmaceuticals|Novartis May 18 2020 --
NCT03345940 Terminated Drug: Fingolimod|Drug: Dimethyl Fumarate Relapsing Remitting Multiple Sclerosis Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Patient-Centered Outcomes Research Institute|Universita degli Studi di Genova April 30 2017 Phase 4
NCT02575365 Terminated Drug: 05 mg Fingolimod Cognition|Brain Volume Loss Novartis Pharmaceuticals|Novartis February 16 2016 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl supplier | purchase Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl cost | Fingolimod (FTY720) HCl manufacturer | order Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl distributor